Vir Biotechnology to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Vir Biotechnology will host a virtual presentation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 11:00 am PT / 2:00 pm ET. The presentation will be led by Phil Pang, M.D., Ph.D., the chief medical officer of Vir. Interested parties can access the live webcast on the Investors section of their website, www.vir.bio, which will be available for 30 days post-event. Vir focuses on treating serious infectious diseases using advanced immunological technologies.
- None.
- None.
SAN FRANCISCO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., chief medical officer of Vir will virtually present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16 at 11:00 am PT / 2:00 pm ET.
A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days.
About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. For more information, please visit www.vir.bio.
FAQ
What is the date and time of Vir Biotechnology's presentation at the H.C. Wainwright Conference?
Who is presenting on behalf of Vir Biotechnology at the conference?
How can I access the live webcast of Vir Biotechnology's presentation?
How long will the archive of Vir Biotechnology's presentation be available?
What is the focus of Vir Biotechnology's research and development?
